May 30, 2019
Predicine today announced a strategic partnership with FMD to help biopharma companies accelerate
biomarker‐driven clinical trials and concurrent New Drug Application (NDA) submissions in the U.S. and
China. The collaboration structure allows for global development of novel oncology therapies for
biopharmaceutical companies, including global clinical trial support, regulatory support, and biomarker‐
driven drug development, and CDx development. Read FMD-Predicine press release.